A recently published study by FMI expects the global Non-Small Cell Lung Cancer Market to augment at a 7.2% CAGR from 2023 to 2033. By the end of the said assessment period, a valuation of US$ 20 Billion is expected for the market. From 2018 to 2022, the industry experienced noteworthy growth, registering a value CAGR of 6.7% and closing at US$ 10 Billion. The expansion of the...